These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 11757083)
1. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Holstein A; Plaschke A; Egberts EH Diabetes Metab Res Rev; 2001; 17(6):467-73. PubMed ID: 11757083 [TBL] [Abstract][Full Text] [Related]
2. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia. Holstein A; Plaschke A; Hammer C; Egberts EH Eur J Clin Pharmacol; 2003 Jun; 59(2):91-7. PubMed ID: 12698302 [TBL] [Abstract][Full Text] [Related]
3. Drug-induced severe hypoglycaemia in Type 2 diabetic patients aged 80 years or older. Greco D; Angileri G Diabetes Nutr Metab; 2004 Feb; 17(1):23-6. PubMed ID: 15163121 [TBL] [Abstract][Full Text] [Related]
4. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Draeger KE; Wernicke-Panten K; Lomp HJ; Schüler E; Rosskamp R Horm Metab Res; 1996 Sep; 28(9):419-25. PubMed ID: 8911976 [TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Dills DG; Schneider J Horm Metab Res; 1996 Sep; 28(9):426-9. PubMed ID: 8911977 [TBL] [Abstract][Full Text] [Related]
6. Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Stahl M; Berger W Diabet Med; 1999 Jul; 16(7):586-90. PubMed ID: 10445835 [TBL] [Abstract][Full Text] [Related]
7. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial. Gallwitz B; Rosenstock J; Patel S; von Eynatten M; Hehnke U; Mehlburger L; Dugi KA; Woerle HJ Diabetes Obes Metab; 2015 Mar; 17(3):276-84. PubMed ID: 25425502 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Schernthaner G; Durán-Garcia S; Hanefeld M; Langslet G; Niskanen L; Östgren CJ; Malvolti E; Hardy E Diabetes Obes Metab; 2015 Jul; 17(7):630-8. PubMed ID: 25761977 [TBL] [Abstract][Full Text] [Related]
9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976 [TBL] [Abstract][Full Text] [Related]
10. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. Charpentier G; Fleury F; Dubroca I; Vaur L; Clerson P Diabetes Metab; 2005 Apr; 31(2):189-95. PubMed ID: 15959425 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial). Terauchi Y; Yamada Y; Ishida H; Ohsugi M; Kitaoka M; Satoh J; Yabe D; Shihara N; Seino Y Diabetes Obes Metab; 2017 Aug; 19(8):1188-1192. PubMed ID: 28294488 [TBL] [Abstract][Full Text] [Related]
12. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Langtry HD; Balfour JA Drugs; 1998 Apr; 55(4):563-84. PubMed ID: 9561345 [TBL] [Abstract][Full Text] [Related]
13. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide. Massi-Benedetti M; Herz M; Pfeiffer C Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study. Gonzalez C; Monti C; Pinzon A; Monsanto H; Ejzykowicz F; Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):592-602. PubMed ID: 30076124 [TBL] [Abstract][Full Text] [Related]
15. Glimepiride: new preparation. Just another hypoglycaemic sulphonylurea agent. Prescrire Int; 1998 Aug; 7(36):106-7. PubMed ID: 10342947 [TBL] [Abstract][Full Text] [Related]
16. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. Martin S; Kolb H; Beuth J; van Leendert R; Schneider B; Scherbaum WA Diabetologia; 2003 Dec; 46(12):1611-7. PubMed ID: 14600814 [TBL] [Abstract][Full Text] [Related]
17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
18. Severe hypoglycaemia in elderly patients with type 2 diabetes and coexistence of cardiovascular history. Piątkiewicz P; Buraczewska-Leszczyńska B; Kuczerowski R; Bernat-Karpińska M; Rabijewski M; Kowrach M Kardiol Pol; 2016; 74(8):779-785. PubMed ID: 27040016 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173 [TBL] [Abstract][Full Text] [Related]
20. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials]. Guo XH; Feng ZK; Xu LH Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492 [No Abstract] [Full Text] [Related] [Next] [New Search]